EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of Angiogenesis in Retinal Diseases and New Advances in Drug Development

Emma Boey, Humza Zaidi, Tina Tang iD, Amirfarbod Yazdanyar iD

Cells · 2025

DOI: 10.3390/cells14231849 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Emma Boey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA. Hauptthemen laut MEDLINE: Drug Development, Neovascularization, Pathologic, Angiogenesis Inhibitors, Retinal Diseases. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation of angiogenesis can cause a disruption in oxygen and nutrient delivery, resulting in impaired neural retinal function. Understanding the underlying components involved in its pathophysiology is essential to develop new treatments for preserving and restoring vision. The aim of this review is to describe the role of angiogenesis in different retinal and choroidal pathologies and evaluate current and emerging anti-angiogenic therapies for retinopathies. Current research articles, focusing on the latest clinical trials from the last two decades, were used to write this review. We discuss normal angiogenesis, in contrast to pathological angiogenesis, in four diseases: retinal vein occlusion (RVO), age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). Alongside these diseases, this review discusses relevant anti-angiogenic therapies that have been approved for use and are under active investigation through clinical trials for their safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentNeovascularization, PathologicAngiogenesis InhibitorsRetinal DiseasesHumansAnimalsMacular DegenerationDiabetes Complications

Stichwörter der Autor:innen

angiogenesis inhibitorsanti-angiogenicdiabetic retinopathyneovascular age-related macular degenerationretinal diseasesretinal vein occlusionretinopathy of prematurity

Substanzen

Angiogenesis Inhibitors

Autor:innen und Institutionen

  • Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.
  • University of Connecticut School of Medicine, 200 Academic Wy, Farmington, CT 06032, USA.
  • Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON M5R 0A3, Canada.
  • Retina Group of New England, 174 Cross Rd, Waterford, CT 06385, USA.

ORCID-Profile: Tina Tang, Amirfarbod Yazdanyar

Zitieren

APA

Boey, E., Zaidi, H., Tang, T., & Yazdanyar, A. (2025). Role of Angiogenesis in Retinal Diseases and New Advances in Drug Development. Cells. https://doi.org/10.3390/cells14231849

Vancouver

Boey E, Zaidi H, Tang T, Yazdanyar A. Role of Angiogenesis in Retinal Diseases and New Advances in Drug Development. Cells. 2025. doi:10.3390/cells14231849

BibTeX
@article{Boey2025,
  author = {Boey, Emma and Zaidi, Humza and Tang, Tina and Yazdanyar, Amirfarbod},
  title = {Role of Angiogenesis in Retinal Diseases and New Advances in Drug Development},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14231849}
}
Kostenlos starten →